CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Interpace Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Interpace Biosciences Inc
Waterview Plaza
Suite 310, 2001 Route 46
Phone: (412) 224-6100p:412 224-6100 PARSIPPANY, NJ  07054  United States Ticker: IDXGIDXG
Business Summary
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
7389 Business services, not elsewhere classified
8071 Medical laboratories
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director Thomas W.Burnell 61 12/1/2020 12/1/2020
Chief Financial Officer ChristopherMccarthy 32 7/24/2023 7/24/2023
Independent Director VijayAggarwal 74 2/1/2022 2/1/2022
3 additional Officers and Directors records available in full report.

Business Names
Business Name
IDXG
Interpace Diagnostics Lab Inc.
Interpace Diagnostics, LLC
Interpace Pharma Solutions, Inc.
miRInform Pancreas
miRInform Thyroid

General Information
Number of Employees: 108 (As of 2/29/2024)
Outstanding Shares: 4,404,795 (As of 9/30/2024)
Shareholders: 191
Stock Exchange: OTC
Federal Tax Id: 222919486
Fax Number: (302) 636-5454
Email Address: Scotugno@pdi-inc.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024